Carbenicillin Indanyl

CHEMBL1596 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
494.6 g/mol
LogP
3.8
Phase
4

An oral ester prodrug of carbenicillin that is absorbed from the gut and then hydrolyzed to release active carbenicillin. It was used to treat urinary tract infections caused by susceptible organisms, particularly Pseudomonas. Its use is largely historical, replaced by fluoroquinolones and other oral agents with better systemic activity.

Molekularmasse

494,6000 g/mol

LogP

3,80

TPSA

138,00 Ų

Lipinski-Regel der Fünf

Bestanden

Wirkmechanismus

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)Oc3ccc4c(c3)CCC4)c3ccccc3)C(=O)N2[C@H]1C(=O)O

InChI

InChI=1S/C26H26N2O6S/c1-26(2)20(24(31)32)28-22(30)19(23(28)35-26)27-21(29)18(15-7-4-3-5-8-15)25(33)34-17-12-11-14-9-6-10-16(14)13-17/h3-5,7-8,11-13,18-20,23H,6,9-10H2,1-2H3,(H,27,29)(H,31,32)/t18?,19-,20+,23-/m1/s1

Molecular Formula

C26H26N2O6S

HBD / HBA

2 / 7

Rotierbare Bindungen

7

Schwere Atome

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

An oral ester prodrug of carbenicillin that is absorbed from the gut and then hydrolyzed to release active carbenicillin. It was used to treat urinary tract infections caused by susceptible organisms, particularly Pseudomonas. Its use is largely historical, replaced by fluoroquinolones and other oral agents with better systemic activity.

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Yes, Carbenicillin Indanyl is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1596. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 93184. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.